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Mitochondrial respirationFatty acids affect insulin secretion via metabolism and FFAR1-mediated signaling. Recent reports indicate that
these two pathways act synergistically. Still it remains unclear how they interrelate. Taking into account the
key role of mitochondria in insulin secretion, we attempted to dissect the metabolic and FFAR1-mediated effects
of fatty acids on mitochondrial function. One-hour culture of MIN6 cells with palmitate signiﬁcantly enhanced
mitochondrial respiration. Antagonism or silencing of FFAR1 prevented the palmitate-induced rise in respiration.
On the other hand, in the absence of extracellular palmitate FFAR1 agonists caused a modest increase in respira-
tion. Using an agonist of the M3 muscarinic acetylcholine receptor and PKC inhibitor we found that in the pres-
ence of the fatty acid mitochondrial respiration is regulated via Gαq protein-coupled receptor signaling. The
increase in respiration in palmitate-treated cells was largely due to increased glucose utilization and oxidation.
However, glucose utilization was not dependent on FFAR1 signaling. Collectively, these results indicate that mi-
tochondrial respiration in palmitate-treated cells is enhanced via combined action of intracellular metabolism of
the fatty acid and the Gαq-coupled FFAR1 signaling. Long-term palmitate exposure reduced ATP-coupling efﬁ-
ciency of mitochondria and deteriorated insulin secretion. The presence of the FFAR1 antagonist during culture
did not improve ATP-coupling efﬁciency, however, it resulted in enhanced mitochondrial respiration and im-
proved insulin secretion after culture. Taken together, our study demonstrates that during palmitate exposure,
integrated actions of fatty acid metabolism and fatty acid-induced FFAR1 signaling on mitochondrial respiration
underlie the synergistic action of the two pathways on insulin secretion.
© 2015 Published by Elsevier B.V.1. Introduction
Free fatty acids (FFAs) play an essential role in the regulation of
insulin secretion. At low glucose levels, FFAs are used as a substrate
for generation of ATP andmaintain insulin secretion [1]. At high glucose
conditions, β-oxidation is inhibited by a product of the glycolytic
pathway, malonyl-CoA, and fatty acids are directed towards formation
of triacylglycerol (TAG) [2,3]. The anabolic and catabolic reactions
between long-chain acyl Co-As (LC-CoA) and TAG, known as
glycerolipid/free fatty acid (GL/FFA) cycle, produce lipid signaling mol-
ecules including LC-CoAs, phosphatic acids, monoacylglycerol and diac-
ylglycerol (DAG), all of which stimulate insulin secretion [4]. In additionvine serum albumin; DAG,
y acid; FFAR1, free fatty acid
protein coupled receptor; GSIS,
phate; LC-CoA, long-chain acyl
rotein kinase C; PLC, phospholi-
palmitoyltransferase 1; TAG,
an).to its role as a nutrient, FFAs serve as ligands and inﬂuence insulin secre-
tion by interacting with G-protein coupled receptors (GPCRs) on the
plasma membrane [5,6]. One of the GPCRs that is highly expressed in
beta cells is the free fatty acid receptor 1 (FFAR1 or GPR40) [5,6]. Activa-
tion of the receptor leads to activation of phospholipase C (PLC) and hy-
drolysis of phosphatidylinositol 4,5-bisphosphate (PIP2) into DAG and
inositol triphosphate (IP3). DAG and IP3 potentiate insulin secretion by
activating protein kinase C (PKC) and triggering ER Ca2+ release, re-
spectively [7,8]. Recently, FFAR1 agonists have been developed as po-
tential therapeutic agents for the treatment of type 2 diabetes [9–12].
In contrast to short-term effects, long-term exposure of beta cells to
FFAs impairs insulin secretion and triggers apoptosis [13]. The deleteri-
ous effects of FFAs have been linked to altered glucose/fatty acid oxida-
tion cycle [13], decreased NADPH content [14], endoplasmic reticulum
(ER) stress [15] and partitioning towards formation of toxic ceramide
species [16]. Also, FFAR1 signaling has been implicated in the long-
term deleterious effects of FFAs [17–20].
We have recently demonstrated that fatty acid metabolism and
FFAR1 signaling act synergistically on insulin secretion [17]. Reduced
β-oxidation of fatty acids in the presence of a FFAR1 antagonist pointed
out mitochondria as a site where the two pathways may converge [17].
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Uncoupling of respiration from ATP synthesis is essential for the regula-
tion of ATP/ADP ratio and insulin secretion [21]; and beta cells depleted
of mitochondria are unable to properly change insulin secretion in re-
sponse tometabolic changes [22,23]. Taking into account the aforemen-
tioned, we decided to investigate the effects of fatty acid metabolism
and FFAR1 signaling on mitochondrial function.
2. Materials and methods
2.1. Culture of cells and human islets
Mouse insulinomaMIN6 cells (a kind gift from Prof. Jun-IchiMiyaza-
ki, Osaka University, Japan) and human HEK293 cells were cultured in
Dulbecco's Modiﬁed Eagle medium (DMEM) (Invitrogen, Carlsbad, CA,
USA) containing 25 mM glucose and supplemented with 10% fetal bo-
vine serum (FBS) (Invitrogen) and 55 μM β-mercaptoethanol at 37 °C
and 5% CO2. Experiments on MIN6 cells were performed between pas-
sages 21–30.
Human islets were obtained from brain-dead otherwise healthy in-
dividuals from the Islet Transplantation Unit at Uppsala University.
Islets were cultured in CMRL 1066 medium (Invitrogen) containing
5.5 mM glucose and supplemented with 10% FBS. Ethical permission
to use human islets was obtained from the Regional Ethical Review
Board in Uppsala (EPN number 2010/006; 2010-02-10).
2.2. Free fatty acid preparation
Palmitate (Sigma Aldrich, St. Louis, MO, USA) was prepared as
100 mM stock solution dissolved in 50% ethanol. Stock solution was di-
luted in culture medium to 0.5 mM concentration and allowed to com-
plex for 30min at 37 °Cwith fatty acid free bovine serumalbumin (BSA)
(Boehringer Mannheim GmbH, Mannheim, Germany) to a ﬁnal molar
ratio of 6.6 to 1 [17].
2.3. Short- and long-term treatment of cells and human islets
Cells/islets were treated with 0.5 mM palmitate (Sigma Aldrich) in
the absence or presence of FFAR1 antagonists; 2 μM ANT203, 2 μM
ANT825 (compound 39 in [24]) (both compounds from AstraZeneca,
Macclesﬁeld, UK) or 10 μM DC260126 (Tocris Bioscience, Bristol, UK).
Short-term treatment was performed for 1 h in XF assay medium
(Seahorse Biosciences, North Billerica, MA, USA) set to pH 7.4 and sup-
plementedwith 25mMglucose. Insulin secretion and oxygen consump-
tion rate (OCR) were measured during culture.
Long-term treatment was performed for 48 h in complete DMEM
culture medium. Glucose-stimulated insulin secretion (GSIS) and OCR
were determined after treatment.
2.4. Down-regulation of FFAR1 by short hairpin RNA
FFAR1 was down-regulated by using the short hairpin RNA (shRNA)
5′-CCGGGCCCGTCTCAGTTTCTCCATTCTCGAGAATGGAGAAACTGAGACGG
GCTTTTT-3′ (Sigma Aldrich). pLKO.1-puro non-Mammalian shRNA
control plasmid DNA (Sigma Aldrich) was used as a negative control.
Transfection was performed in 96-well plates by adding 50,000 cells to
a mixture containing 1 μl Lipofectamine 2000 (Invitrogen) and
0.3 μg DNA in 50 μl OptiMEM (Invitrogen). After overnight incuba-
tion, the transfectionmediumwas replaced with the culture medium
for another 72 h.
2.5. Measurement of FFAR1 mRNA level by real-time PCR
Total mRNA was isolated from MIN6 cells using NucleoSpin® RNA
(Macherey-Nagel, Duren, Germany) and reversely transcribed into
cDNA with SuperScript™ III First-Strand Synthesis System for RT-PCR(Invitrogen). The real-time PCR was performed in 10 μl volume using
Dynamo Capillary SYBR Green qPCR kit (Finnzymes, Espoo, Finland).
The following primers were used for ampliﬁcation: FFAR1 (forward
primer, 5′-CCATTCTGCTCTTCTTTCTG-3′ and reverse primer, 5′-GGGT
TTATGAAACTAGCCAC-3′), β-actin (forward primer, 5′-TCTGTGTGGA
TTGGTGGCTC-3′ and reverse primer, 5′-GACTCATCGTACTCCTGCTT
GCT-3′). FFAR1 mRNA level was normalized to the housekeeping gene
β-actin using the following formula: target amount = 2−ΔΔCt, where
ΔΔCt = [Ct (GPR40 KO)− Ct (β-actin KO)] − [Ct (GPR40 control) −
Ct (β-actin control) [25].
2.6. Oxygen consumption measurements
Mitochondrial respiration was determined bymeasuring OCR in the
Extracellular Flux Analyzer XF96e (Seahorse Biosciences). Assays were
performed in XF assay medium (Seahorse Biosciences) set to pH 7.4
and supplemented with 25 mM glucose.
Mitochondrial functionwas determined bymeasuring basal respira-
tion, ATP-coupled respiration, proton leak and maximal respiratory ca-
pacity. Basal OCR was measured during the last 30 min of 1-h culture.
All measurements were corrected for non-mitochondrial OCR, which
was measured by adding inhibitors of electron transport chain; rote-
none (5 μM) and antimycin (5 μM). Mitochondrial OCR was estimated
by subtracting OCR measurement after rotenone/antimycin addition
from OCR measurement before oligomycin addition. ATP-coupled
respiration was assessed by the addition of ATP synthase inhibitor
oligomycin (4 μM). OCR measurement after oligomycin addition was
subtracted from OCR measurement before oligomycin addition. The
drop in OCR induced by oligomycin addition reﬂects ATP-coupled respi-
ration. Proton leak OCR was estimated by subtracting OCR measure-
ment after addition of rotenone/antimycin from OCR measurement
after addition of oligomycin. Maximal respiratory capacity was deter-
mined by adding 4 μM ionophore FCCP.
OCR was, in addition, measured in the presence of FFAR1 agonists
TUG-499 (2 μM) (Merck Millipore, Darmstadt, Germany) and
AS2034178 (2 μM) (Tocris Bioscience). Also, OCR was measured in the
presence of 2-deoxyglucose (2-DG) (100 mM), carnitine palmitoyl-
transferase 1 (CPT1) inhibitor etomoxir (40 μM), agonist of M3 musca-
rinic acetylcholine receptor carbachol (100 μM) and PKC inhibitor
chelerythrine (10 μM). Concentrations of the compounds were deter-
mined in optimization experiments. Compounds were obtained from
Sigma Aldrich if not indicated.
2.7. Measurements of palmitate oxidation and glucose utilization
Palmitate oxidation and glucose utilization were determined by in-
cluding during culture 2 μCi [3H]palmitate and 2 μCi d-[5-3H]glucose, re-
spectively. Blanks for each conditionwere created by adding radioactive
compounds tomedium. After 1-h treatments,mediawere transferred to
1.5-ml tubes. Then tubes were placed inside scintillation vials contain-
ing 500 μl of H2O. The scintillation vials were sealed and incubated at
56 °C overnight to permit 3H2O formed by the cells to evaporate and
equilibrate with water in the vials [26]. The vials were then cooled
to room temperature. After removing the tubes, 15 ml Ultima
Gold™ scintillation ﬂuid (PerkinElmer) was added to the water and
3H2O content determined by a liquid-scintillation spectrometer
(Wallac System 1400™ PerkinElmer, Boston, MA). The average num-
ber of disintegrations in blank tubes was subtracted from experi-
mental measurements.
2.8. Measurements of mitochondrial DNA
Total DNA was isolated using QIAamp DNA Mini Kit (Qiagen, Hilden,
Germany). The real-time PCR was performed using Dynamo Capillary
SYBR Green qPCR kit (Finnzymes, Espoo, Finland). mtDNAwas ampliﬁed
using primers against ND1 gene (5′-ATTACTTCTGCCAGCCTGAC-3′
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DNAwas ampliﬁed using primers against β-actin gene (5′-CCCTACAGTG
CTGTGGGTTT-3′ (forward) and 5′-GAGACATGCAAGGAGTGCAA-3′ (re-
verse)). Changes in mtDNA number were calculated using the following
formula: target amount = 2−ΔΔCt, where ΔΔCt= [Ct (ND1 treat)− Ct
(β-actin treat)]− [Ct (ND1 control)− Ct (β-actin control).Fig. 1. Short-term palmitate exposure enhancesmitochondrial respiration via FFAR1. MIN6 cell
ence of 0.5mMpalmitate (P), 2 μMANT203, 2 μMANT825 or 10 μMDC260126 for 1 h. A. Amoun
point is amean±SDof 5 replicates. 5 μMoligomycin, 4 μMFCCPandmixture of 5 μMof rotenon
OCR. F. Proton leak OCR. G.Mitochondrial DNA amount. H.Mitochondrial OCR in human islets. A
way ANOVA (with Bonferroni's post hoc test) (A, C–F), paired t-test (G and H). * vs control, #2.9. GSIS
After 48-h treatments, MIN6 cells were incubated for 30 min at
37 °C in the presence of 2 mM glucose in buffer containing
125 mM NaCl, 5.9 mM KCl, 1.2 mM MgCl2, 1.3 mM CaCl2 and
25 mM HEPES, titrated to pH 7.4 with NaOH, and supplementeds (A–G) or human islets (H) were cultured in XF assaymedium in the absence (C) or pres-
t of insulin secretedduring exposure. B. OCR from a representative experimentwhere each
e and 5 μMantimycinwere added as indicated. C andD.Mitochondrial OCR. E. ATP-coupled
, C–H. Data aremean±SEMof 3–6 independent experiments. Statistical analysis: RM one-
vs palmitate. p b 0.05 was considered statistically signiﬁcant.
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GmbH, Germany). After this incubation period, the buffer was
changed to the same type of buffer containing either 2 or 20 mM
glucose. Cells were incubated for 30 min and then aliquots of the
buffer were collected [17].
Insulin was determined by a competitive ELISA and normalized to
intracellular protein content. To isolate protein, cells were washed
with PBS and lysed in the same buffer with the addition of 1% Triton
X100 and 0.4%protease inhibitor cocktail (both obtained fromSigmaAl-
drich). Protein content in the lysates was determined by the DC Protein
Assay (BioRad, Hercules, CA, USA).2.10. Statistical analysis
All analysis and ﬁgure presentation was done with Graph Pad Prism
software, version 6 (San Diego, CA, USA). Paired t-test and repeated
measures one-way ANOVA (with Bonferroni post hoc test and Fishers
LSD test) were used for statistical analysis. p b 0.05 was considered sta-
tistically signiﬁcant.3. Results and discussion
3.1. Short-term palmitate exposure enhances mitochondrial respiration via
FFAR1
MIN6 cells cultured for 1 h in the presence of palmitate secreted 50%
more insulin than in the absence of the fatty acid (Fig. 1A). This was ac-
companied by a 35% rise inmitochondrial OCR (Fig. 1B andC). Inhibition
of the FFAR1 signaling pathway with the receptor antagonist ANT203
prevented the palmitate-induced rise in insulin secretion (Fig. 1A).
The effect was associated with a signiﬁcant reduction in OCR to levels
close to those observed in control cells (Fig. 1B and C). In the absence
of palmitate, ANT203 showed no effects on insulin secretion and OCR
(Fig. 1A, B and C). Similar results were obtained when structurally dif-
ferent antagonists DC260126 [27] or ANT825 [24] were used in combi-
nation with palmitate (Fig. 1D). Palmitate- and ANT203-induced
changes in OCRwere due to proportionate changes in ATP-coupled res-
piration and proton leak (Fig. 1E and F). Mitochondrial DNA amount
was not affected by treatments suggesting that the observed effects
were due to changes in bioenergetics (Fig. 1G).
The role of FFAR1 in palmitate-induced elevation of OCRwas veriﬁed
in human islets. One-hour treatment of the islets with palmitate in-
creased OCR by ~35% (Fig. 1H). When ANT203 was also present during
culture, OCR was signiﬁcantly lowered (Fig. 1H).
To further conﬁrm the role of FFAR1 in the regulation of mitochon-
drial respiration, we knocked down the expression of the receptor by
using shRNA technique. With this approach mRNA level of the receptor
was reduced by 25–35% (Fig. 2A). When FFAR1-deﬁcient MIN6 cells
were treated with palmitate for 1 h, no statistically signiﬁcant changes
in OCR were observed (Fig. 2B).
Finally, to validate the role of FFAR1 in the regulation of mitochon-
drial respiration, the human cell line HEK293 that does not express
the receptor [5] was cultured with or without palmitate and ANT203.Fig. 2. Short-term palmitate exposure does not enhance mitochondrial respiration in
FFAR1-deﬁcient MIN6 and HEK293 cells. MIN6 cells (A and B) or HEK293 cells (C) were
cultured in XF assay medium in the absence (C) or presence of 0.5 mM palmitate (P).
A. The FFAR1 mRNA level was normalized to the actin mRNA level and presented as fold
control in MIN6 cells transfected with FFAR1 shRNA or a negative control shRNA (neg).
B.Mitochondrial OCR in the transfectedMIN6 cells in the absence or presence of palmitate.
C. Mitochondrial OCR in HEK293 cells. Data are mean ± SEM of 4 independent experi-
ments. Statistical analysis: paired t-test (A), RM one-way ANOVA (with Bonferroni's
post hoc test) (B and C). * vs control transfected with negative shRNA, # vs palmitate
transfected with negative shRNA. p b 0.05 was considered statistically signiﬁcant.
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ANT203 induced no changes in OCR (Fig. 2C).
Taken together our ﬁndings demonstrate that the palmitate-
induced increase in mitochondrial respiration is dependent on FFAR1
signaling.Fig. 3. Gαq protein-coupled signaling enhances mitochondrial respiration in the presence of ex
presence of 0.5 mM palmitate (P), 2 μM AS2034178, 2 μM TUG-499 or 10 μM ANT203 for 1 h.
each point is a mean ± SD from 5 replicates. Carbachol (100 μM), chelerythrine (10 μM) and AN
mitate-treated cells in the absence or presence of ANT203. E. Effect of ANT203 onmitochondrial
are mean± SEM of 3–6 independent experiments. Statistical analysis: RM one-way ANOVA (w
control, # vs palmitate, & vs. corresponding condition without ANT203. p b 0.05 was considere3.2. Gαq protein-coupled signaling enhances mitochondrial respiration in
the presence of extracellular palmitate
To further validate the role of FFAR1 signaling,MIN6 cellswere treat-
ed with FFAR1 agonists TUG469 or AS2034178. The agonists inducedtracellular palmitate. MIN6 cells were cultured in XF assay medium in the absence (C) or
A. Effect of FFAR1 agonists on OCR. B and D. OCR from representative experiments where
T203 (2 μM)were added as indicated. C. Effect of carbachol on mitochondrial OCR in pal-
OCR in palmitate-treated cells in the absence or presence of chelerythrine. A, C and E. Data
ith Fisher's LSD test) (A), RM one-way ANOVA (with Bonferroni's post hoc test) (C–E). * vs
d statistically signiﬁcant.
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enhancesmitochondrial respiration via combined action of intracellular
fatty acid metabolism and FFAR1 signaling.
Next, we explored the role of Gαq-dependent signaling in the
regulation of OCR. This was done by stimulating the Gαq-coupled M3
muscarinic acetylcholine receptor. Addition of the receptor agonist, car-
bachol, to palmitate-treated cells caused a modest increase in OCR (Fig.
3B). However, when ANT203 was also present during culture, the in-
crease in OCR was more pronounced (Fig. 3B). In the absence of extra-
cellular palmitate, carbachol caused minor changes in OCR (Fig. 3B).Fig. 4. Intracellular metabolism of palmitate enhances glucose utilization whereas FFAR1 signal
absence (C) or presence of 0.5 mM palmitate (P), 40 μM etomoxir, 100 mM 2-deoxyglucose, 2
etomoxir, 100 mM 2-deoxyglucose and 2 μM ANT203 were added as indicated. OCR from rep
oxidation during 1-h treatment estimated by the formation of 3H2O from 3H-labeled palmitat
determined by the formation of 3H2O from d-[5-3H]glucose. B, D, and E. Data are mean ± SE
one-way ANOVA (with Bonferroni's post hoc test) (E). * vs control, # vs palmitate. p b 0.05 waAltogether, it suggests that signaling of other Gαq protein-coupled re-
ceptors may also interplay with metabolism and affect mitochondrial
respiration of beta cells.
ER Ca2+ release and protein kinase C (PKC) are downstreammedia-
tors of Gαq-dependent signaling [7]. The importance of Ca2+ for mito-
chondrial function is well established. It has been demonstrated that
the activity of three key mitochondrial dehydrogenases and ATP
synthase is sensitive to Ca2+ [28–30]. Moreover, IP3-dependent Ca2+
release to mitochondria is required for efﬁcient mitochondrial respira-
tion of eukaryotic cells [31]. The importance of PKC for mitochondrialing enhances mitochondrial function. MIN6 cells were cultured in XF assay medium in the
μM ANT203, 2 μM AS2034178 or 2 μM TUG-499 for 1 h. A, C, and F. During culture, 40 μM
resentative experiments where each point is a mean ± SD from 5 replicates. B. Palmitate
e. D. Reduction in OCR after addition of 2-DG. E. Glucose utilization during 1-h treatment
M of 3–4 independent experiments. Statistical analysis: paired t-test (B and D) and RM
s considered statistically signiﬁcant.
Fig. 5. FFAR1 signaling is involved in ampliﬁcation of insulin secretion by etomoxir in the
presence of extracellular palmitate. MIN6 cells were cultured in XF assay medium in the
absence (C) or presence of 0.5 mM palmitate (P), 2 μM ANT203 or 40 μM etomoxir for
1 h. A. Mitochondrial OCR during the culture. B. Amount of insulin secreted during expo-
sure. Data are mean ± SEM of 6 independent experiments. Statistical analysis: RM one-
wayANOVA (with Bonferroni's post hoc test). * vs control, # vspalmitate, & vspalmitate+
etomoxir. p b 0.05 was considered statistically signiﬁcant.
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stem cells [32,33]. To further explore the role of Gαq protein-coupled
signaling, we examined the involvement of PKC in FFAR1-mediated reg-
ulation of mitochondrial respiration. When PKC inhibitor chelerythrine
was added toMIN6 cells, OCRwas lowered. The decreasewasmore pro-
nounced in palmitate-treated cells, however, suggesting that the
palmitate-induced increase in OCR is PKC-dependent (Fig. 3D). When
ANT203 was added to the cells, where chelerythrine was present,
reduction of OCR was less than in the presence of palmitate alone
(Fig. 3D and E) implying that FFAR1-mediated effects on mitochondrial
respiration involve PKC.
3.3. Intracellular metabolism of palmitate enhances glucose utilization
whereas FFAR1 signaling enhances mitochondrial function
Wenext asked if the observed rise inOCRduring the palmitate expo-
sure was due to elevated oxidation of the fatty acid. When β-oxidation
was inhibited in palmitate-treatedMIN6 cells by adding the CPT1 inhib-
itor etomoxir, OCRwas lowered only transiently andmodestly (Fig. 4A).
At the same time, palmitate oxidation was effectively inhibited bymore
than 50% under these conditions as determined by using 3H-palmitate
(Fig. 4B). These results indicate that the contribution of β-oxidation to
the increase in OCR is minor. When glycolysis was inhibited by the ad-
dition of the non-metabolisable glucose analog 2-DG, OCRwas lowered
in control and in palmitate-treated cells (Fig. 4C). The reduction was
more accentuated in palmitate-treated cells, however. It suggests that
the rise in OCR in palmitate-treated cells was largely due to increased
glucose oxidation (Fig. 4C and D). In line with these results, in the pres-
ence of palmitate glucose utilizationwas increased compared to control
cells (Fig. 4E).We asked if the FFAR1 signaling pathway elevates OCR by
enhancing glucose utilization. Surprisingly, FFAR1 antagonist ANT203
did not reduce glucose utilization (Fig. 4E). Furthermore, FFAR1 agonists
TUG-499 and AS2034178 in the absence of extracellular palmitate did
not affect glucose utilization (Fig. 4E). These results suggest that
FFAR1 signaling elevates OCR by enhancing mitochondrial function
rather than glucose utilization. Indeed, when the antagonist was
added to palmitate-treated MIN6 cells, OCR was rapidly reduced by
15–20% irrespective of the absence or presence of 2-DG or etomoxir
(Fig. 4F).
Studies addressing the contribution of FFAR1 to the regulation of in-
tracellular metabolism are controversial. Steneberg et al. showed that
overexpression of FFAR1 in beta cells leads to perturbations in glucose
and fatty acid metabolism [34]. On the other hand, Alquer et al. ob-
served no changes in intracellular metabolism of islets isolated from
FFAR1 knockout mice [35]. The discrepancy may be explained by the
differences in the level of circulating free fatty acids. As it is evident
from our study, FFAR1 signaling signiﬁcantly affects intracellular
metabolism in the presence of high palmitate. Further support to the
involvement of FFAR1 in the regulation ofmetabolism provides a recent
study that demonstrates that FFAR1 pathway affects glycerolipid
formation [36].
3.4. FFAR1 signaling is involved in ampliﬁcation of insulin secretion by
etomoxir in the presence of extracellular palmitate
Increased generation of metabolites via GL/FFA cycle stimulates in-
sulin secretion. To address the involvement of the FFAR1 pathway in
GL/FFA cycle-induced stimulation of insulin secretion, we directed
fatty acids towards accumulation by inhibiting β-oxidation with
etomoxir. When etomoxir was present during culture with palmitate
OCR was slightly elevated (Fig. 5A). As expected, palmitate-induced
insulin secretion was further ampliﬁed in the presence of etomoxir
(Fig. 5B). When ANT203was also present during culture with palmitate
and etomoxir, mitochondrial respiration and insulin secretion were re-
duced to control levels (Fig. 5A and B). These results suggest that FFAR1signaling is required for ampliﬁcation of insulin secretion by accumulat-
ed fatty acid species.
Based on our ﬁndings we propose a model of fatty acid-induced
stimulation of insulin secretion (Fig. 6). Intracellular metabolism of
fatty acids enhances glucose utilization and elevates the level of
glycerol-3-phosphate required for the formation of triacylglycerols. In
parallel, beta cells sense extracellular fatty acids via FFAR1 and respond
by enhancingmitochondrial function. It facilitates oxidation of metabo-
lites from the already accelerated glycolytic pathway. Elevated genera-
tion of ATP initiates and maintains energy-demanding GL/FFA cycling
[4] and, thereby, stimulates insulin secretion. In support of this
Fig. 6. A model of integrated action of intracellular fatty acid metabolism and FFAR1 signaling on mitochondrial activity and insulin secretion. At high palmitate (P), intracellular metab-
olism of the fatty acid enhances glucose utilization and elevates the level of glycerol-3-phosphate (Gro-3P) required for the formation of triacylglycerols (TAG). In parallel, beta cells sense
extracellular fatty acids via FFAR1. Activation of the receptor leads to the activation of phospholipase C and hydrolysis of phosphatidylinositol 4,5-bisphosphate into diacylglycerol (DAG)
and inositol triphosphate (IP3). DAG and IP3 activate protein kinase C (PKC) and trigger ER Ca2+ release, respectively. It leads to enhanced mitochondrial function, which facilitates oxi-
dation of glucose metabolites from the already accelerated glycolytic pathway. Elevated generation of ATP initiates and maintains glycerolipid/FFA cycle and, thereby, stimulates insulin
secretion. In parallel, increased PKC activity and increased ER Ca2+ release directly stimulate insulin secretion,which constitutes a small portion of total secreted insulin. Blue lines—action
of intracellular metabolism of fatty acids. Red lines—action of FFAR1 signaling. Purple lines—actions dependent on two pathways.
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cells GL/FFA cycle is inhibited in the presence of FFAR1 antagonist [36].
The proposed model does not exclude mitochondria-independent
action of FFAR1 signaling on insulin secretion. We and others have
demonstrated that a FFAR1 agonist potentiates insulin secretion in the
absence of extracellular fatty acid, although to a much lesser extent
[17,37].3.5. Presence of FFAR1 antagonist during long-term palmitate exposure re-
sulted in elevatedmitochondrial respiration and preserved insulin secretion
After 48-h exposure to palmitate, glucose-stimulated insulin secre-
tion (GSIS) from MIN6 cells was attenuated to 40% of that in control
cells (Fig. 7A). Also, insulin content was reduced by 65% (Fig. 7B). Sur-
prisingly, OCR in palmitate-treated cells was almost similar to OCR in
non-treated cells (Fig. 7C and D). However, ATP-coupled OCR was
slightly reduced whereas proton leak OCR was slightly elevated
(Fig. 7E and F). As a result, ATP-coupling efﬁciency (the ratio between
ATP-coupled and proton leak OCR) was reduced from 2.1 in control
cells to 1.5 in palmitate-treated cells (Fig. 7G). When ANT203 was also
present during palmitate exposure, GSIS and insulin content were pre-
served (Fig. 7A and B). At the same time, mitochondrial OCR was in-
creased to levels signiﬁcantly higher than in control cells (Fig. 7C and
D). Similar elevation was observed when two other structurally dissim-
ilar antagonists, DC260126 and ANT825, were used (Fig. 7D). However,
ATP-coupling efﬁciency was not improved (Fig. 7E, F and G). Amount of
mitochondrial DNA was not affected by culture conditions indicating
that the observed drastic effect of the antagonist on OCR was not
accounted for by a change in mitochondrial number (Fig. 7H).The role of FFAR1 in the regulation ofmitochondrial respiration dur-
ing the long-term exposure to palmitate was further addressed by
shRNA-mediated silencing of the receptor. We found that after 48-h
treatment with palmitate OCR was highly elevated in FFAR1-silenced
cells but not in cells transfected with control vector encoding non-
mammalian shRNA (Fig. 7I).
Increased proton leak may, at least partially, explain the impaired
GSIS after long-term culture with palmitate. In beta cells, uncoupling
plays an important role in the control of ATP/ADP ratio [21]. It has
been demonstrated that increased levels of mitochondria carrier pro-
tein, uncoupling protein 2 (UCP2), alter GSIS [38,39]. Mechanisms by
which fatty acids uncouple respiration include cycling between the pro-
tonated and the unprotonated forms [40] and changes in mitochondrial
ﬁssion-fusion events [41]. The role of uncoupling in beta cells is contro-
versial, however. Although it is often regarded as being detrimental, it
also has a cytoprotective role due to diminished reactive oxygen species
(ROS) production [42–44]. However, the FFAR1 antagonist was unable
to improve ATP-coupling efﬁciency in our study suggesting that intra-
cellular action of fatty acid plays themajor role in the uncoupling of mi-
tochondria. Instead, by attenuating respiration and lowering insulin
secretion during culture, the antagonist preserved fuel and insulin con-
tent and thereby enhanced mitochondrial respiration and improved in-
sulin secretion after culture. Studies have demonstrated that inhibition
of FFAR1 during long-term palmitate exposure lowers generation of
ROS and alleviates apoptosis [17,18,20,45,46]. Interestingly, in one
study FFAR1 agonist TUG-469 was also protective during culture with
palmitate.We assume that itmight be due to partial agonistic properties
of the compound that could make it act as an antagonist when com-
bined with such a strong agonist as palmitate [47]. Taking into account
the major contribution of mitochondrial electron transport chain to the
Fig. 7. Presence of FFAR1 antagonist during long-term palmitate exposure resulted in elevatedmitochondrial respiration and preserved insulin secretion. MIN6 cells were cultured in the
absence (C) or presence of 0.5mMpalmitate (P),with orwithout 2 μMANT203, 2 μMANT825 or 10 μMDC260126 for 48 h. After culture, GSIS, insulin content, OCR andmitochondrial DNA
amountwere determined. A. GSIS during 30min. B. Insulin content. C. OCR from a representative experiment where each point is amean± SD of 5 replicates. 5 μMoligomycin, 4 μMFCCP
andmixture of 5 μMof rotenone and 5 μMantimycinwere added as indicated. D and E.Mitochondrial OCR. F. Mitochondrial OCR in cells transfectedwith either FFAR1 shRNA or negative
control shRNA. G. ATP-coupled OCR. H. Proton leak OCR. I. ATP-coupling efﬁciency (ratio between ATP-coupled and proton leak OCR). J. Mitochondrial DNA amount. A, B, D–J. Data are
mean± SEMof 3–5 independent experiments. Statistical analysis: RM one-way ANOVA (with Bonferroni's post hoc test) (A–I), paired t-test (J). * vs control, # vs palmitate, & vs palmitate
transfected with negative shRNA. p b 0.05 was considered statistically signiﬁcant.
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drial respiration during culture, a FFAR1 antagonist reduces ROS gener-
ation and in such a way, lowers apoptosis.
4. Conclusions
In summary, during palmitate exposure, integrated action of intra-
cellular metabolism of the fatty acid and Gαq-coupled FFAR1 signaling
on mitochondrial respiration underlies the synergistic action of the
two pathways on insulin secretion.
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